Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Study of NL005 in Healthy Chinese Volunteers
NCT04555850Phase 1Completed
- Sponsor
- Northland Biotech
- Start
- Jul 2018
- Primary completion
- Feb 2019
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gletimbetasin in acute myocardial infarction (AMI) (4 arms), sponsored by Northland Biotech. Primary endpoints: Maximum Tolerated Dose, Number of participants with treatment-related adverse events and 9 more. Started Jul 2018; status: completed.
02
Drugs
gletimbetasin
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT04555850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04555850.